Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Hannah Heinonen

Registered Nurse, School Aberdeen, WA Nurse Practitioner

NPI 1811516362 CMS profile 10765831

1006 N H St Fl 3, Warren Medical Services Bldg, Aberdeen, WA 98520

Open in the dashboard

General payments

$154

6 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Heinonen of Aberdeen, WA is reported in the CMS Open Payments database as having received $154 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Registered Nurse, School profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84 3
2024 General $50 2
2023 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Heinonen
  • Registered Nurse, School median
  • Middle half of Registered Nurse, School
  • National median

In program year 2025, general payments to Hannah Heinonen were reported at $84. Among 35 Registered Nurse, School profiles paid that year, the median was $119 and the middle half received between $36 and $155.

Show as a table
Year Hannah Heinonen Registered Nurse, School median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 — — $132
2022 $0 $29 $18–$125 $149
2023 $20 $39 $21–$122 $160
2024 $50 $75 $26–$338 $164
2025 $84 $119 $36–$155 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. GlaxoSmithKline, LLC. $43 2 payments
  2. Pfizer Inc. $40 1 payment
  3. Organogenesis Inc. $27 1 payment
  4. Amgen Inc. $24 1 payment
  5. Exact Sciences Corporation $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $154 6 payments
Products named General payments · program years 2023–2025
  1. Otezla $24 1 payment
  2. REPATHA $24 1 payment
  3. BEXSERO $24 1 payment
  4. AREXVY $20 1 payment
  5. Cologuard Collection Kit $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,141

Median for Registered Nurse: 109

Drug cost

$86,154

Median for Registered Nurse: $4,454

Branded share of claims

14.6%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 16 $28,770
Jardiance Empagliflozin Brand 28 $21,446
Ozempic Semaglutide Brand 18 $20,121
Ventolin Hfa Albuterol Sulfate Brand 20 $1,547
Atorvastatin Calcium Generic 69 $952
Rosuvastatin Calcium Generic 61 $889
Losartan Potassium Generic 65 $870
Levothyroxine Sodium Generic 65 $866
Gabapentin Generic 43 $743
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $690

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BEXSERO
  • GlaxoSmithKline, LLC. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, School in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record